Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q2 2021 · 10-Q
Revenue$30.28K$30.28K−32.1% vs Q2 2020 Net Income-$1.30M-$1.30MN/M vs Q2 2020 EPS Diluted-$0.02-$0.02N/M vs Q2 2020 Gross Profit$29,784−10.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flowderived-$135,934N/M Margins · derivedGross margin98.3%+23.7 pt vs Q2 2020
Operating margin-1882.4%−533.9 pt vs Q2 2020
Net margin-4281.7%−619.1 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 23, 2021 · 54 d after period end